Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Quest Diagnostics (DGX) to $185 from $180 and keeps an In Line rating on the shares following what the firm calls “a solid 2Q performance” as well as an uplift in 2025 guidance. The firm, which cites improved business trends, excluding policy impacts, for its target increase, sees Quest having “manageable risks and a path forward for growth beyond 2026.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $191 from $182 at Morgan Stanley
- Quest Diagnostics price target raised to $180 from $175 at UBS
- Quest Diagnostics price target raised to $192 from $190 at Truist
- Quest Diagnostics price target raised to $178 from $160 at Deutsche Bank
- Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating